Table 2 Overall survival in NEC cohort and invasive mammary carcinoma cohort according to clinical stage (2003–2009)
Cohort | n | Median survival in months (IQR) | 5-year OS rate (95% CI) | P |
|---|---|---|---|---|
All | <0.0001 | |||
NEC | 135 | 26 (12–48) | 53.6 (42.2-63.7) | |
IMC | 374,598 | 34 (16–56) | 79.8 (79.6-79.9) | |
Stage I | 0.002 | |||
NEC | 32 | 33 (17–51) | 74.4 (43.4-90.0) | |
IMC | 170,778 | 36 (18–58) | 89.6 (89.2-89.6) | |
Stage II | <0.0001 | |||
NEC | 49 | 30 (19–52) | 73.9 (56.3-85.3) | |
IMC | 123,430 | 36 (17–58) | 82.4 (82.1-82.7) | |
Stage III | 0.014 | |||
NEC | 16 | 19 (13–41) | 58.2 (21.0-82.8) | |
IMC | 41,422 | 29 (14–48) | 72.4 (71.8-73.1) | |
Stage IV | NS | |||
NEC | 32 | 12 (4–25) | 20.7 (5.70-42.1) | |
IMC | 17,830 | 15 (5–30) | 27.9 (26.9-29.0) |